World Drug Report 2019
Methodology Report

Research and Trend Analysis Branch
UNODC, Vienna
# Table of Contents

1. **Introduction** .......................................................................................................................... 1
   Sources of information .............................................................................................................. 1

2. **Data on drug use and health consequences of drug use** ................................................ 4
   Overview ................................................................................................................................ 4
   Indicators ............................................................................................................................... 7
   Extrapolation methods ........................................................................................................... 9
   *Adjustment for differences in age groups* ............................................................................ 9
   *Extrapolation of results from lifetime prevalence to annual prevalence* ......................... 9
   *Extrapolations based on school surveys* ............................................................................. 11
   *Extrapolations based on treatment data* ............................................................................. 11
   National, regional and global estimates of the number of people who use drugs and the health consequences of drug use .............................................................................................. 12
   *Estimates of the total number of people who used illicit drugs at least once in the past year* ......................................................................................................................... 13
   *Estimates of the number of ‘problem drug users’* ............................................................ 14
   *Calculation of drug use perception indices* ....................................................................... 16
   *Calculation of regional and global estimates of cannabis use among 15-16 years old students* ................................................................................................................................. 19
   *Estimates of the prevalence of injecting drug use, HIV and hepatitis (C and B virus) among people who inject drugs (PWID)* ................................................................. 27
   *Estimates on the number of drug-related deaths (mortality)* ............................................ 32

3. **Drug cultivation, production and manufacture** ............................................................... 32
   Net cultivation .......................................................................................................................... 35
   Indirect estimation of illicit opium poppy cultivation ............................................................. 36
   Yield and production .............................................................................................................. 39

4. **Drug trafficking** ............................................................................................................... 45
   Seizures ................................................................................................................................ 45
   Trafficking routes and volumes ............................................................................................ 50
   Drug price and purity data ...................................................................................................... 52
1. Introduction

Considerable efforts have been made over the years to improve the estimates presented in the *World Drug Report*, which rely, to a large extent, on information submitted by Member States through the Annual Reports Questionnaire (ARQ). Nonetheless, challenges remain in producing such estimates because of the gaps and the varying quality in the available data. One major problem is the heterogeneity in the completeness and the time frame of data coverage in ARQs reported by Member States. Irregular reporting may result in absence of data for some years and may also influence the reported trend in a given year. In addition, submitted questionnaires are not always comprehensive, and much of the data collected are subject to limitations and biases. These issues affect the reliability, quality and comparability of the information received.

Sources of information

Under the International Drug Conventions, Member States are formally required to provide national drug control related information annually to the ‘Secretary General’ of the United Nations (i.e. the Secretariat in the UNODC). For this purpose, the Commission on Narcotic Drugs in 2010 endorsed the revised Annual Reports Questionnaire (ARQ) that is sent to Member States each calendar year for submission of responses and information on the drug situation.

The World Drug Report 2019 is based on data primarily obtained from the ARQs submitted by Governments to UNODC. The data collected in the current ARQ normally refer to the drug situation in 2017. Out of 199 potential respondents to the ARQ for 2017 (including 193 Member States), UNODC received 108 replies to its questionnaire on the “Extent and patterns of and trends in drug use (ARQ Part III)” and 112 replies to Part IV on “Extent and patterns and trends in drug crop cultivation, manufacturing and trafficking”. Europe, had the best coverage (92 per cent of the respondents provided a reply), followed by Asia (67 per cent) and the Americas (60 per cent). In the case of Africa, only 31 per cent of the Member States, and in the Oceania region, only two out of the 16 countries, responded to the Annual Report Questionnaire.

In general, the quantity of information provided on illicit drug supply is significantly better than that of information provided on drug demand. Analysis of responses to Part IV of the
ARQ revealed that 81 per cent of them were ‘substantially’ completed compared to 67 per cent of Part III (ARQs with completion rates higher than 50 per cent were classified as having been ‘substantially filled in’; ARQs with completion rates lower than 50 per cent were classified as having been ‘partially filled in’).

In order to analyse the extent to which Member States provided information, a number of key questions in the ARQ were identified:

- For Part III, on the extent and patterns and trends of drug abuse, the key questions used for the analysis referred to: trends in drug use, for which 73 per cent of the respondents returning the ARQ provided information; prevalence of different drugs among the general population, for which 64 per cent of the respondents provided information; for prevalence of drug use among youth 63 per cent responded; for drug related mortality 57 per cent and for treatment demand 81 per cent. On average, for the countries which submitted Part III to UNODC, the overall response rate of completion was 63 per cent. However, this analysis does not take into account the completeness or quality of the information provided in response to each of the areas mentioned.

- For Part IV, on the extent and patterns and trends in drug crop cultivation, manufacturing and trafficking, the analysis included replies to the questions on: the quantities seized, for which 97 per cent of the Member States returning the ARQ provided the information; on trafficking of illicit drugs, for which 86 per cent of these Member States provided responses; on prices and purity 86 per cent of the Member States responded, and on persons brought into formal contact with the police and/or the criminal justice system in connection with drug-related offences, which 84 per cent of the Member States provided information. The overall analysis of these data revealed that the overall response rate completion was 67 per cent for Part IV. However, this analysis does not take into account the completeness of responses of the quality of information provided in each of sections mentioned.

Information provided by Member States in the ARQ form the basis for the estimates and trend analysis provided in the World Drug Report. Often, this information and data is not sufficient to provide an accurate or comprehensive picture of the world’s drug markets. When
necessary and where available, the data from the ARQ are thus supplemented with data from other sources.

As in previous years, seizure data made available to UNODC via the ARQ was complemented primarily with data from other government sources, such as other official communication with UNODC, official national publications, data provided to UNODC by the Heads of National Law Enforcement Agencies (HONLEA) at their regional meetings, and data published by international and regional organisations such as Interpol/ICPO, World Customs Organization, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the Inter-American Drug Abuse Control Commission (CICAD). Price data for Europe were complemented with data from Europol. Demand related information was obtained through a number of additional sources, including the national assessments of the drug situation supported by UNODC, the drug control agencies participating in the UNODC’s ‘Drug Abuse Information Network for Asia and the Pacific’ (DAINAP), as well as various national and regional epidemiological networks such as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) or the Inter-American Drug Abuse Control Commission (CICAD). Reports published by National governments and academic research published in the scientific literature were also used as additional sources of information. This type of supplementary information is useful and necessary as long as Member States lack the monitoring systems necessary to produce reliable, comprehensive and internationally comparable data.

To this end, UNODC encourages and supports the improvement of national monitoring systems. Major progress has been made in the area of illicit crop monitoring over the last few years in some of the countries that have major illicit crop cultivations. In close cooperation with UNODC and with the support of major donors – these countries have developed impressive monitoring systems designed to identify the extent of, and trends in, the cultivation of narcotic plants. These data form a fundamental basis for trend analysis of illicit crop cultivation and drug production presented in the World Drug Report.

There remain significant data limitations on the demand side. Despite commendable progress made in several Member States, in the area of prevalence estimates for example, far more remains to be done to provide a truly reliable basis for trend and policy analysis and needs assessments. The work currently being done on the World Drug Report provides yet another
opportunity to emphasize the global need for improving the evidence base available to the policy makers and programme planners.

2. Data on drug use and health consequences of drug use

Overview

UNODC estimates of the extent of illicit drug use in the world have been published periodically since 1997. Assessing the extent of drug use (the prevalence and estimates of the number of drug users) is a particularly difficult undertaking because it involves in most settings measuring the size of a ‘hidden’ population. Regional and global estimates are reported with ranges to reflect the information gaps. The level of confidence expressed in the estimates varies across regions and drug types.

A global estimate of the level of use of a specific drug involves the following steps:

1. Identification and analysis of appropriate sources (starting from the ARQ);

2. Identification of key benchmark figures for the level of drug use in all countries where data are available (annual prevalence of drug use among the general population aged 15-64) which then serve as ‘anchor points’ for subsequent calculations;

3. ‘Standardization’ of existing data if reported with a different reference population than the one used for the World Drug Report (for example, from age group 12 and above to a standard age group of 15-64);

4. Adjustments of national indicators to estimate an annual prevalence rate if such a rate is not available (for example, by using the lifetime prevalence or current use rates; or lifetime or annual prevalence rates among the youth population). This includes the identification of adjustment factors based on information from countries in the region with similar cultural, social and economic situations where applicable;

5. Imputation for countries where data are not available, based on data from countries in the same subregion. Ranges are calculated by considering the 10th and 90th weighted percentile of the subregional distribution, using the target population in the countries as weights;
6. Extrapolation of available results for a subregion were calculated only for subregions where prevalence estimates for at least two countries covering at least 20% of the population were available. If, due to a lack of data, subregional estimates were not extrapolated, a regional calculation was extrapolated based on the 10th and 90th percentile of the distribution of the data available from countries in the region. Since the World Drug Report 2018, when this methodology was revised, a weighted percentile procedure has been used that takes into account the population aged 15-64 in the countries.

7. Aggregation of subregional estimates rolled-up into regional results to arrive at global estimates.

For countries that did not submit information through the ARQ, or in cases where the data were older than 10 years, other sources were identified, where available. In nearly all cases, these were government sources. Many estimates needed to be adjusted to improve comparability (see below).

In cases of estimates referring to previous years, the prevalence rates are unchanged and applied to new population estimates for the year 2017. Currently, only a few countries measure prevalence of drug use among the general population on an annual basis. The remaining countries that regularly measure it - typically the more economically developed - do so usually every three to five years. Therefore, caution should be used when interpreting any change in national, regional or even global prevalence figures, as changes may in part reflect newer reports from countries, at times with changed methodology, or the exclusion of older reports, rather than actual changes in prevalence of a drug type.

In particular, this year presents the inclusion of newly available data from two largely populated Member States: India and Nigeria. In recent previous reports, the latest available drug use information for Nigeria dated back to 2007, while no information was available for India as India’s previous national survey had taken place in 2000/2001. Thus, the results of these surveys were no used longer in recent years. Therefore, the inclusion of these new figures greatly affects the prevalence estimates for certain drug types at the regional and global levels.
Information on drug use prevalence for Nigeria is taken from the drug use survey recently conducted by UNODC and the national government\(^1\), while the information regarding India is obtained from a report on drug use released by the Ministry of Social Justice and Empowerment in 2019\(^2\). Information on the prevalence of opiates in India is obtained directly from the authors of the report.

Detailed information on drug use is available from countries in North America, a large number of countries in Europe, a number of countries in South America, the two large countries in Oceania and a limited number of countries in Asia and Africa. For the World Drug Report 2019, new estimates of prevalence of drug use among the general population for the year 2017 were available for 16 countries, while one Member State provided data for the year 2018.

One key problem in national data is the level of accuracy, which varies strongly from country to country. Not all estimates are based on sound epidemiological surveys. In some cases, the estimates simply reflect the aggregate number of drug users found in drug registries, which cover only a fraction of the total drug using population in a country. Even in cases where detailed information is available, there is often considerable divergence in definitions used, such as chronic or regular users; registry data (people in contact with the treatment system or the judicial system) versus survey data (usually extrapolation of results obtained through interviews of a selected sample); general population versus specific surveys of groups in terms of age (such as school surveys), special settings (such as hospitals or prisons), or high risk groups, et cetera.

To reduce the error margins that arise from simply aggregating such diverse estimates, an attempt has been made to standardize - as a far as possible - the heterogeneous data set. All available estimates were transformed into one single indicator – annual prevalence among the general population aged 15 to 64 – in most instances using regional average estimates and using transformation ratios derived from analysis of the situation in neighbouring countries. The basic assumption is that though the level of drug use differs between countries, there are general patterns (for example, young people consume more drugs than older people; males consume more drugs than females; people in contact with the criminal justice system show


higher prevalence rates than the general population, et cetera) which apply to most countries. It is also assumed that the relationship between lifetime prevalence and annual prevalence among the general population or between lifetime prevalence among young people and annual prevalence among the general population, except for new or emerging drug trends, do not vary greatly among countries with similar social, cultural and economic situations.

UNODC does not publish estimates of the prevalence of drug use in countries with smaller populations (less than approximately 100,000 population aged 15-64) where the prevalence estimates were based on the results of youth or school surveys that were extrapolated to the general adult population, as applying such methods in the context of small countries can result in inaccurate figures.

**Indicators**

The most widely used indicator at the global level is the annual prevalence rate: the number of people who have consumed an illicit drug at least once in the twelve months prior to the study. Annual prevalence has been adopted by UNODC as one of key indicators to measure the extent of drug use. It is also part of the Lisbon Consensus on core epidemiological indicators of drug use which has been endorsed by the Commission on Narcotic Drugs. The key epidemiological indicators of drug use are:

1. Drug consumption among the general population (prevalence and incidence);
2. Drug consumption among the youth population (prevalence and incidence);
3. High-risk drug use (number of injecting drug users and the proportion engaged in high-risk behaviour, number of daily drug users);
4. Utilization of services for drug problems (treatment demand);
5. Drug-related morbidity (prevalence of HIV, hepatitis B virus and hepatitis C virus among drug users);
6. Drug-related mortality (deaths attributable to drug use).

Efforts have been made to present the overall drug situation from countries and regions based on these key epidemiological indicators.
The use of annual prevalence is a compromise between lifetime prevalence data (drug use at least once in a lifetime) and data on current use (drug use at least once over the past month). The annual prevalence rate is usually shown as a percentage of the youth and adult population. The definitions of the age groups vary, however, from country to country. Given a highly skewed distribution of drug use among the different age cohorts in most countries, differences in the age groups can lead to substantially diverging results.

Applying different methodologies may also yield diverging results for the same country. In such cases, the sources were analysed in-depth and priority was given to the most recent data and to the methodological approaches that are considered to produce the best results. For example, it is generally accepted that nationally representative household surveys are reasonably good approaches to estimating cannabis, ATS or cocaine use among the general population, at least in countries where there are no adverse consequences for admitting illicit drug use. Thus, household survey results were usually given priority over other sources of prevalence estimates.

When it comes to the use of opiates (opium, heroin, and other illicit opiates), injecting drug use, or the use of cocaine and ATS among regular or dependent users, annual prevalence data derived from national household surveys tend to grossly under-estimate such use, because heroin or other problem drug users often tend to be marginalized or less socially integrated, and may not be identified as living in a ‘typical’ household (they may be on the streets, homeless or institutionalized). Therefore, a number of ‘indirect’ methods have been developed to provide estimates for this group of drug users, including benchmark and multiplier methods (benchmark data may include treatment demand, police registration or arrest data, data on HIV infections, other services utilization by problem drug users or mortality data), capture-recapture methods and multivariate indicators. In countries where there was evidence that the primary ‘problem drug’ was opiates, and an indirect estimate existed for ‘problem drug use’ or injecting drug use, this was preferred over household survey estimates of heroin use. Therefore, for most of the countries, prevalence of opioid or opiates use reported refers to the extent of use of these substances measured through indirect methods.

For other drug types, priority was given to annual prevalence data found by means of household surveys. In order to generate comparable results for all countries, wherever
needed, the reported data was extrapolated to annual prevalence rates and/or adjusted for the preferred age group of 15-64 for the general population.

**Extrapolation methods**

*Adjustment for differences in age groups*

Member States are increasingly using the 15-64 age group, though other groups are used as well. Where the age groups reported by Member States did not differ significantly from 15-64, they were presented as reported, and the age group specified. Where studies were based on significantly different age groups, results were typically adjusted. A number of countries reported prevalence rates or number of drug users for the age groups 15+ or 18+. In such cases, adjustments were generally based on the assumption that there was no significant drug use above the age of 64; the reported number of drug users based on the population age 15+ (or age 18+) was shown as a proportion of the population aged 15-64.

*Extrapolation of results from lifetime prevalence to annual prevalence*

Some countries have conducted surveys in recent years without asking the question whether drug consumption took place over the last year. In such cases, results were extrapolated to reach annual prevalence estimates. For example, country X in West and Central Europe reported a lifetime prevalence of cocaine use of 2%. As an example, taking data for lifetime and annual prevalence of cocaine use in countries of West and Central Europe, it can be shown that there is a strong positive correlation between the two measures (correlation coefficient $R = 0.94$); that is, the higher the lifetime prevalence, the higher the annual prevalence and vice versa. Based on the resulting regression line (with annual prevalence as the dependent variable and lifetime prevalence as the independent variable) it can be estimated that a country in West and Central Europe with a lifetime prevalence of 2% is likely to have an annual prevalence of around 0.7% (see figure). Almost the same result is obtained by calculating the ratio of the unweighted average of annual prevalence rates of the West and Central European countries and the unweighted average lifetime prevalence rate ($0.93/2.61 = 0.356$) and multiplying this ratio with the lifetime prevalence of the country concerned ($2\% * 0.356 = 0.7\%$).
A similar approach was used to calculate the overall ratio by averaging the annual/lifetime ratios, calculated for each country. Multiplying the resulting average ratio (0.334) with the lifetime prevalence of the country concerned provides the estimate for the annual prevalence (0.387 * 2% = 0.8%). There is a close correlation observed between lifetime and annual prevalence (and an even stronger correlation between annual prevalence and monthly prevalence). Solid results (showing small potential errors) can only be expected from extrapolations done for a country in the same region. If instead of using the West and Central European average (0.387), the ratio found in the USA was used (0.17), the estimate for a country with a lifetime prevalence of cocaine use of 2% would instead amount to 0.3% (2% * 0.17). Such an estimate is likely to be correct for a country with a drug history similar to the USA, which has had a cocaine problem for more than two decades, as opposed to West and Central Europe, where the cocaine problem is largely a phenomenon of the last decade. Therefore, data from countries in the same subregion with similar patterns in drug use were used, wherever possible, for extrapolation purposes.

Both approaches—the regression model and the ratio model—were used to determine upper and lower uncertainty range estimates calculated at a 90% confidence interval among those
aged 15-64 years in the given country. The greater the range, the larger the level of uncertainty around the estimates. The range for each country is reported in the statistical annex, where available.

**Extrapolations based on school surveys**

Analysis of countries which have conducted both school surveys and national household surveys shows that there is, in general, a positive correlation between the two variables, particularly for cannabis, ATS and cocaine. The correlation, however, is weaker than that of lifetime and annual prevalence or current use and annual prevalence among the general population. But it is stronger than the correlation between opiate use and injecting drug use and between treatment demand and extent of drug use in the general population.

These extrapolations were conducted by using the ratios between school surveys and household surveys of countries in the same region or with similar social structure where applicable. As was the case with extrapolation of results from lifetime prevalence to annual prevalence, two approaches were taken: a) the unweighted average of the ratios between school and household surveys in the comparison countries with an upper and lower uncertainty range estimate calculated at a 90% confidence interval; and b) a regression-based extrapolation, using the relationships between estimates from the other countries to predict the estimate in the country concerned, with an upper and lower uncertainty range estimate calculated at a 90% confidence interval. The final uncertainty range and best estimate are calculated using both models, where applicable.

**Extrapolations based on treatment data**

For a number of developing countries, the only drug use-related data available was drug users registered or treatment demand. In such cases, other countries in the region with a similar socio-economic structure were identified, which reported annual prevalence and treatment data. A ratio of people treated per 1,000 drug users was calculated for each country. The results from different countries were then averaged and the resulting ratio was used to extrapolate the likely number of drug users from the number of people in treatment.
National, regional and global estimates of the number of people who use drugs and the health consequences of drug use

For this purpose, the estimated prevalence rates of countries were applied to the population aged 15-64, as provided by the United Nations Population Division for the year 2016.

In the tables presented in the World Drug Report for regional and global estimates, totals may not add up due to rounding.

Ranges have been produced to reflect the considerable uncertainty that arises when data are either extrapolated or imputed. Ranges are provided for estimated numbers and prevalence rates in the Report. Larger ranges are reported for subregions and regions with less certainty about the likely levels of drug use – in other words, those regions for which fewer direct estimates are available, for a comparatively smaller proportion of the region’s population, or for regions for which the existing estimates show a comparatively larger variability.

Countries with one published estimate (typically those countries with a representative household survey, or an indirect prevalence estimate that did not report ranges) did not have uncertainty estimated. This estimate is reported as the ‘best estimate’.

To account for populations in countries with no published estimate, the 10th and 90th percentile in the range of direct estimates within the subregion was used to produce a lower and upper estimate. Similarly to the World Drug Report 2018, in this report a weighted percentile procedure was implemented, that takes into account the population in the 15-64 age group in each country. For example, there are four countries in the Near and Middle East / South-West Asia subregion with sufficiently recent past year prevalence estimates for cocaine use: Afghanistan (0.00, a point estimate), Iran (Islamic Republic of) (0.00 – 0.01, best estimate 0.01), Israel (0.50 – 0.70, best estimate 0.60) and Pakistan (0.00 – 0.04, best estimate 0.01). In order to obtain a best estimate for the subregion, the weighted average of the best estimates for prevalence over these three countries is applied to the population of the remaining countries in the subregion without prevalence data. To obtain a range for the subregion, the weighted 10th percentile of the lower bounds of the uncertainty ranges (0.00, 0.00, 0.50 and 0.00), namely 0.00, and the 90th percentile of the upper bounds (0.00, 0.01, 0.70 and 0.04), namely 0.04, were considered. It is important to note that, as Israel accounts for only about 3 per cent of the population within the 15-64 age group in these four countries, the resulting weighted percentiles are not heavily influenced by the higher prevalence present
in this country. The percentages of 0.00 and 0.04 were applied to the population of the remaining countries without prevalence data, in combination with the national level data for Afghanistan, Iran (Islamic Republic of), Israel and Pakistan, to derive subregional lower and upper estimates of 0.01 and 0.04 per cent respectively.

In some cases, not all the regions in a subregion had sufficient country-level data to allow the above calculations. In such cases, for the purposes of arriving at estimates at regional level, lower and upper estimates at the sub-regional level were derived based on the data points from the entire region, specifically by considering the weighted 10th and 90th percentiles respectively of the lower and upper country-level estimates. These results were then combined with the other subregions to arrive at upper and lower estimates, and hence best estimates, at regional level.

This produces conservative (wide) intervals for subregions where there is geographic variation and/or variance in existing country-level estimates; but it also reduces the likelihood that skewed estimates will have a dramatic effect on regional and global figures, as the weighted percentiles procedure will give a smaller weight to relatively small countries, which tend to be more likely to present an extreme prevalence.

As in the World Drug Report 2018, in this report the region of Oceania was divided into four subregions (Australia and New Zealand, Melanesia, Micronesia, and Polynesia), while in previous years no subregional estimates of annual prevalence among the population aged 15-64 were available. Given that the data for Melanesia, Micronesia and Polynesia is scarce, in order to avoid imputing these regions with data from only Australia and New Zealand, the closest five countries to these regions with available data were considered in the calculations, when necessary. This was the case for the calculations of the prevalence of cocaine, “ecstasy”, opiates and opioids.

*Estimates of the total number of people aged 15-64 who used illicit drugs at least once in the past year*

This year’s Report used the same approach as in the previous years. Two ranges were produced, and the lowest and highest estimate of each the approaches were taken to estimate the lower and upper ranges, respectively, of the total drug using population. This estimate is obviously tentative given the limited number of countries upon which the data informing the two approaches were based. The two approaches were as follows:
Approach 1:
The global estimates of the number of people using each of the five drug groups in the past year were added up. Taking into account that people use more than one drug type and that these five populations overlap, the total was adjusted downward. The size of this adjustment was made based upon household surveys conducted in 26 countries globally including countries from North America (Canada, Mexico and the United States, Europe (including Italy, Germany, Spain and England and Wales), Latin America (Argentina, Brazil, Plurinational State of Bolivia, Chile, Peru and Uruguay), Asia and the Pacific (Israel, Indonesia, Philippines, and Australia) and Africa (Algeria), which assessed all five drug types, and reported an estimate of total illicit drug use. Across these studies, the extent to which adding each population of users over estimated the total population was a median factor of 1.12. The summed total was therefore divided by 1.12

Approach 2:
This approach was based on the average proportion of the total drug using population that comprises cannabis users. The average proportion was obtained from household surveys conducted in the same countries as for Approach 1. Across all of these studies, the median proportion of total drug users that comprised cannabis users was 81 per cent. The range of cannabis users at the global level was therefore divided by 0.813.

The global lower estimate was the lower of the two values obtained from the two approaches, while the upper estimates was the upper value derived from the two approaches described.

Estimates of the number of ‘problem drug users’
It is useful to make estimates of the number of drug users whose use is particularly problematic, as a proxy to those who could be diagnosed with drug use disorders, as this subgroup of drug users is most likely to come to the attention of health and law enforcement. Moreover, this subgroup’s drug use has been estimated to cause the main burden of disease and public order.

The number of problem drug users is typically estimated with the number of people with drug use disorders. Sometimes, an alternative approach is used. The EMCDDA has been using a definition of ‘injecting or long duration use of opioids, amphetamines or cocaine’ to guide
country-level indirect prevalence estimation studies of problem drug use. Indirect methods used include the use of treatment multipliers and capture re-capture methods.

In this Report, as in previous years, each of the five range estimates of the number of people using each of the five drug groups was converted into a ‘heroin user equivalent’. This was calculated with ‘relative risk coefficients’ (see below) derived from the UNODC Harm Index. This method enables the aggregation of results from different drugs into one reference drug.

**Table: Relative risk coefficient**

<table>
<thead>
<tr>
<th></th>
<th>Treatment index</th>
<th>IDU</th>
<th>Toxicity</th>
<th>Deaths index</th>
<th>Relative risk coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Index</strong></td>
<td><strong>Index</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opiates</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Cocaine</td>
<td>85.3</td>
<td>47.8</td>
<td>88</td>
<td>18.5</td>
<td>59.9</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>20.1</td>
<td>59.5</td>
<td>32</td>
<td>6.8</td>
<td>29.6</td>
</tr>
<tr>
<td>Ecstasy</td>
<td>3.8</td>
<td>6.1</td>
<td>20.7</td>
<td>1</td>
<td>7.9</td>
</tr>
<tr>
<td>Cannabis</td>
<td>9</td>
<td>0</td>
<td>1.5</td>
<td>0.6</td>
<td>2.8</td>
</tr>
</tbody>
</table>

A lower range was calculated by summing each of the five lower range estimates; the upper end of the range was calculated by summing the upper range of the five estimates.

To obtain an estimate of the number of ‘problem drug users’, these totals were multiplied by the corresponding proportion of past year heroin users in the United States National Survey on Drug Use and Health (range 53-68% over the recent rounds of this survey). Hence, the LOW estimate is the lower proportion (53%) multiplied by the lower estimated size of the heroin use equivalent population (43.5 million heroin user equivalents). The HIGH estimate is the higher proportion (68%) multiplied by the higher estimated size of the heroin use
equivalent population (69.1 million heroin user equivalents). This gives a range of 23 to 47 million problem drug users globally.

**Calculation of trends based on qualitative information (drug use perception indices)**

In addition to estimates on the extent of drug use, member states also provide UNODC with qualitative information on their perceptions of drug use trends. Such trends are typically based on a multitude of indicators, including general population prevalence data, school surveys, treatment data, emergency room visits, mortality data, reports by social workers, health care officials and law enforcement officers, arrest data, seizure data, media reports, etc.. Based on this information a simple index has been created. For reports of “large increase” 2 points were allocated, for “some increase” 1 point; for “stable” 0 points; for “some decrease” 1 point was deducted and for “large decrease” 2 points were deducted. The points calculated for each year were subsequently added to the accumulated points of the previous year to arrive the drug use perception index. The year 2006 was chosen as the starting year of the index.

Results for cannabis indicate rather strong increases over the 2006-2009 period, followed by a period of only minor increases though again stronger increases in 2016.

**Example of calculation of qualitative information on trends in cannabis global cannabis use (cannabis use perception trend index):**

<table>
<thead>
<tr>
<th>Points*</th>
<th>Cannabis use perception trend index</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cannabis use perception (accumulated points; 1998 =100)</td>
</tr>
<tr>
<td>1998</td>
<td>0</td>
</tr>
<tr>
<td>1999</td>
<td>59</td>
</tr>
<tr>
<td>2000</td>
<td>46</td>
</tr>
<tr>
<td>2001</td>
<td>50</td>
</tr>
<tr>
<td>2002</td>
<td>60</td>
</tr>
<tr>
<td>2003</td>
<td>40</td>
</tr>
<tr>
<td>2004</td>
<td>51</td>
</tr>
<tr>
<td>2005</td>
<td>35</td>
</tr>
<tr>
<td>2006</td>
<td>45</td>
</tr>
<tr>
<td>2007</td>
<td>45</td>
</tr>
<tr>
<td>2008</td>
<td>30</td>
</tr>
<tr>
<td>2009</td>
<td>36</td>
</tr>
<tr>
<td>2010</td>
<td>16</td>
</tr>
</tbody>
</table>
The calculated cannabis use perception index – with a base year of 0 in 1998 - reached 641 points by 2017 suggesting that cannabis use increased over the 1998-2017 period.

In order to put these results into context, it may be interesting to compare them with potential results of all countries that had reported “some increase”, “stable” or “some decline” each year.

On average close to 83 countries per year reported cannabis use trends over the 1998-2017 period to UNODC. If all reporting countries had seen each year a “stable” situation the drug use perception index would have remained unchanged at 0; if all reporting countries had seen “some increase”, the index would have reached 1,584 points by 2017 and in case all reporting countries had seen “some decline” the index would have attained -1,584 points by 2017. If all countries had reported a “strong increase” each year, the index would have increased to 3,168 points and in case that all countries had reported a “strong decline” each year, the index would have amounted to -3,168 points.
In the World Drug Report these results were compared to trends derived from the annually estimated global numbers of cannabis users. While the latter numbers showed an upward trend over the last decade, existing error margins around these estimates do not allow to make a statement of whether the number of cannabis users has indeed increased over the last two decades. However, the qualitative information on reported trends in cannabis use provides an additional indication that overall cannabis use is very likely to have increased over the last two decades.
Global trends in number of cannabis users and qualitative information on trends in cannabis use, 1998–2017

Source: UNODC, responses to the annual report questionnaire.

**Calculation of regional and global estimates of cannabis use among 15-16 years old students, and estimates of any illicit drug use among 15-16 years old students**

In 2018, UNODC undertook in the World Drug Report – for the first time ever – an estimate of the annual prevalence of cannabis use among 15-16 years old students, based on available data from 130 countries. In 2019, the World Drug Report presents not only updated estimates of annual prevalence of cannabis use again, but also estimates of any illicit drug use prevalence among 15-16 years old students.

The age group “15-16 years” was chosen as this is the “preferred” age group for “youth” that is asked in UNODC’s annual report questionnaire. This age group was also chosen by ESPAD which regularly provides data from some 35 European countries on drug and alcohol use. This age group is also available from the surveys among 10th graders undertaken annually under the Monitoring the Future project in the United States, funded by the National Institute on Drug Abuse (NIDA), and from a number of other countries.
Cannabis use prevalence rates typically increase with age until around 18-20 years before declining again thereafter with age. This also means that for most countries cannabis use prevalence rates among 15-16 years old students turn out to be rather similar to the broader group of students aged 12-18 (with those aged 12-14 showing lower rates and those aged 17-18 showing higher rates). Thus, for the United States the annual cannabis use prevalence rates amongst 10th graders turn out to be very similar to those found amongst 8th, 10th and 12th graders combined. Similarly, in Colombia annual prevalence of cannabis use amongst 12 to 18 years old students was found to have been very similar to the rates found among 15-16 years old students. The same applies to students in Pakistan as well. Cannabis use prevalence rates among students aged 15-16 are thus reasonably good proxies for cannabis use among the overall student population aged 12-18. They are thus the preferred indicator for measuring student drug use at the international level as is also reflected in the question on student drug use in UNODC’s annual report questionnaire.

The methodology chosen to calculate the global average of cannabis use among students aged 15-16 years was very similar to the methodology used to calculate cannabis use among the general population aged 15-64:

1. Listing – on a sub-regional basis – the latest annual prevalence rates of cannabis use among the population aged 15-16 (which in most cases reflected school surveys) and multiplying such percentages with the average population of those aged 15-16 in those countries in 2017.

2. For the remaining countries that reported prevalence data on cannabis use (but not the requested age group of not annual prevalence the following adjustments/extrapolations were done:

   a. Adjusting surveys using different age groups to a likely estimate for the population aged 15-16 years; the age adjustments were done based on detailed data from the United Stated for countries in North America, Europe and the developed countries of the Oceania region (i.e. Australia and New Zealand); for Africa and Asia based on detailed data available from Pakistan and for South America, Central America and the Caribbean based on detailed data available from Colombia.
A special model was developed for the adjustments. In short, taking into account considerations of diversity and representativity, the following data served as benchmarks for the calculation of the conversion ratios: the 2013 survey in Colombia among people aged 12-65\(^3\), the 2012 survey carried out in Pakistan jointly by UNODC and the Government of Pakistan targeting the population aged 15-64\(^4\) and the 2015 National Survey on Drug Use and Health of the United States among people aged 12 years and older\(^5\). After collating or generating prevalence data broken down by age groups, prevalence data were derived for each single-year age group. In cases where robust data were not available at this level of granularity (e.g. prevalence data available only for the age brackets 15-19, 20-24, 25-29, etc.), the prevalence in single-year age groups was estimated by optimizing for smoothness the prevalence data as a function of age - subject to the constraints that the total number of users within each given age bracket remained unchanged (i.e. equal to the prevalence multiplied by the population within the specific age bracket). Where necessary boundary conditions were imposed, e.g. a prevalence of 0 for ages 10 and below. On the basis of single-year prevalence estimates obtained, the prevalence rates were estimated for each possible age group that could potentially arise (e.g. 10-15, 12-19, 14-22). Finally, the conversion factors were calculated as the ratios of the prevalence data within the respective age groups as compared to the age groups of interest (age 15-16 years).

b. Extrapolating available life-time or past month data of cannabis use from individual countries to (missing) annual prevalence data based on a regression analysis of other countries in the subregion providing both life-time and annual data among youth or both past month and annual data among youth. A 95 per cent confidence interval was then used to calculate, in addition, a minimum and a maximum estimate based on such regression data.

\(^3\) Gobierno Nacional de la República de Colombia, Estudio Nacional de Consumo de Sustancias Psicoactivas en Colombia – 2013.
\(^4\) UNODC, Drug Use in Pakistan 2013.
3. For the remaining countries which did not report any prevalence data it was assumed that – on average – they had similar prevalence rates as the population weighted average of the reporting countries in the subregion. In cases where the reporting countries accounted for less than 20 per cent of the total population of the subregion, the (weighted) average of reporting countries in the region as a whole was used instead.

4. For countries not reporting any prevalence data it was assumed that the lower estimate was equivalent to the (population weighted) 10th percentile of the reporting countries in the subregion (or the region if reporting countries in the subregion accounted for less than 20 per cent of total population in the subregion) while the upper estimate was equivalent to the (population weighted) 90th percentile of the reporting countries in the subregion (or the data for the region was used as a proxy if reporting countries in the subregion accounted for less than 20 per cent of the total population in the subregion).

The reported ranges reflected primarily the coverage of a region by student surveys; in short, the larger the reported error margins, the less countries reported school survey data in a region or sub-region to UNODC. Error margins turned out to be small for Europe and the Americas where a majority of countries undertook such school surveys in recent years while they were rather large for Africa, Asia or for the Oceania region (with the exception of the economically advanced countries in this region).

5. The totals of the calculated subregional estimates gave the regional estimates and the total of the regional estimates then gave the global estimates.

6. The number of cannabis users was shown for a hypothetical average age of 15-16 years; in order to calculate the total number of cannabis users of those aged 15 years and 16 years the totals had to be still multiplied by two (in order to be in line with the approach used to show general population estimates for those aged 15-64)

As mentioned before, in this year’s report UNODC also created an estimate on the number of users aged 15-16 worldwide that have consumed any illicit drug in the last 12 months. The methodology used for this estimate replicates the ‘Approach 2’ through which the prevalence
of any illicit drug use is calculated for the general population aged 15-64, as previously described.

As explained, this methodology examines the relationship between cannabis use prevalence and any illicit drug use prevalence in the target population to estimate the latter based on the former. The analysis of information from 51 different countries, representing South, Central and North America, Europe, Oceania and Asia, yields that the observed median ratio between cannabis and any illicit drug use annual prevalence for the target population is 90 per cent. Based on this, the total number of any illicit drug users in the 15-16 age group worldwide was estimated directly from the global estimate of cannabis drug users in the same age group.

**The analysis of drug consumption based on the analysis of waste-water is an alternative method to estimate drug consumption**

The development of analytical tools and methods for the waste-water analysis took place in recent years in Europe by waste-water research institutes under the umbrella of the COST initiative (Sewage Analysis CORe group Europe under the European Cooperation in Science and Technology initiative), supported by the European Union under the EU Framework Programme Horizon 2020. Both EU and non-EU countries participate in this cooperation.

In order to obtain – as far as possible – comparable data, waste-water in various cities has been analysed by the research institutes participating in the COST exercise over a one-week period each year in spring.

The analysis was done for the main cocaine metabolite (benzoylcegonine) as well as for amphetamine, methamphetamine and ecstasy.

The approach used is exemplified for the case of benzoylcegonine, the main cocaine metabolite found in waste-water. The amount of benzoylcegonine found each day in the waste-water was determined and a daily average was calculated. (This is important as cocaine use is typically more widespread during the weekend than during normal weak days).

In a subsequent step the size of the population responsible for the waste-water in the respective waste-water catchment areas was determined and the results were shown in terms of average milligrams of benzoylcegonine (a main cocaine metabolite) per day found in waste-water per 1000 inhabitants.

The waste-water data used for the analysis in the World Drug Report can be found under:
Even though the results from the analysis of waste-water have been obtained applying high levels of scientific rigour, the subsequent analysis of the trends at the European level has remained a challenge due to the fact that different cities across Europe took part in this exercise in different years over the 2011-2018 period and differences of cocaine consumption across European cities continue to be quite significant. This means that the inclusion or the exclusion of a specific city can have a significant impact on the overall average. In other words, calculating and comparing the averages of the cities participating each year in the survey may lead to misleading results as a growing participation of cities with lower levels of cocaine consumption could well offset increases in overall cocaine consumption.

This problem can be overcome by analysing the results of the cities which participated each year in this exercise. However, such results would be based on the results of less than 10 cities and the data from such a limited number of cities are not necessarily a reliable indicator for overall cocaine consumption trends in Europe.

An alternative approach used and shown in the report was to expand the analysis to 78 European cities participating in at least one year in the study analysing bencoylecgonine in waste-water (including 13 cities in 2011, 19 in 2012, 30 in 2013, 40 in 2014, 41 in 2015, 52 in 2016, 52 in 2017 and 80 in 2018) as reported to UNODC. UNODC included in its calculations only cities that were geographically located within Europe, i.e. not included were cities being part of European countries that are located outside of Europe.

Interpolation techniques were used to account for missing data. First data from the 78 cities were entered as reported from individual cities. In case of data gaps between years it was assumed that there was a gradual increase or decline in per capita results between the two data points (using the Excel function Series, Trend, Growth). In case of missing data at the
beginning or at the end of the data series, the latest reported data (from other years) was used to fill the data gaps. This method helped to reduce the bias due to the reporting of additional cities (or the non-reporting of other cities) in specific years while making better use of reported data, thus reducing potential trend distortions.

In order to calculate a European average, the city results were weighted by the respective population living in the respective waste-water catchment areas. Based on this method the consumption of cocaine in Europe appears to have increased by 56 per cent over the 2011-2018 period, from 278 mg of benzoylecgonine per day found in waste-water per 1,000 inhabitants in 2011 to 433 mg of benzoylecgonine per day found in waste-water per 1,000 inhabitants in 2018.

This increase is – probably - still a conservative estimate for the actual rise as the model assumes no further changes after the latest reported data (i.e. using 2016 data as a proxy for 2018 data if no further data were reported after 2016).

The method of interpolations used for calculating the averages is shown below based on a hypothetical example of data from four cities:

**Hypothetical sample: data of benzoylecgonine per 1000 inhabitants in four cities**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>City A</td>
<td>80</td>
<td>78</td>
<td>75</td>
<td>80</td>
<td>92</td>
<td>95</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>City B</td>
<td></td>
<td>55</td>
<td>60</td>
<td></td>
<td>85</td>
<td>90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>City C</td>
<td>150</td>
<td>154</td>
<td></td>
<td>174</td>
<td>180</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City D</td>
<td>140</td>
<td></td>
<td>115</td>
<td>120</td>
<td>125</td>
<td>127</td>
<td>130</td>
<td></td>
</tr>
</tbody>
</table>
Interpolation method* used for dealing with missing data for calculating the averages

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>City A</td>
<td>80</td>
<td>78</td>
<td>75</td>
<td>80</td>
<td>92</td>
<td>93</td>
<td>95</td>
<td>97</td>
</tr>
<tr>
<td>City B</td>
<td>55</td>
<td>55</td>
<td>60</td>
<td>67</td>
<td>76</td>
<td>85</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>City C</td>
<td>150</td>
<td>154</td>
<td>160</td>
<td>167</td>
<td>174</td>
<td>180</td>
<td>180</td>
<td>180</td>
</tr>
<tr>
<td>City D</td>
<td>140</td>
<td>131</td>
<td>123</td>
<td>115</td>
<td>120</td>
<td>125</td>
<td>127</td>
<td>130</td>
</tr>
</tbody>
</table>

*using Excel growth function for filling in data within a time series and assuming no change after latest year available

Reported population living in waste-water catchment areas in cities A, B, C, D

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>City A</td>
<td>120,000</td>
<td>125,000</td>
<td>126,000</td>
<td>128,000</td>
<td>130,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City B</td>
<td></td>
<td>210,000</td>
<td>215,000</td>
<td></td>
<td>220,000</td>
<td>225,000</td>
<td>225,000</td>
<td></td>
</tr>
<tr>
<td>City C</td>
<td>60,000</td>
<td>65,000</td>
<td></td>
<td>75,000</td>
<td>77,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City D</td>
<td>150,000</td>
<td></td>
<td>170,000</td>
<td>175,000</td>
<td>177,000</td>
<td>180,000</td>
<td>182,000</td>
<td></td>
</tr>
</tbody>
</table>

Interpolation method* used for estimating population living in waste-water catchment areas in cities A, B, C, D

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>City A</td>
<td>120,000</td>
<td>125,000</td>
<td>126,000</td>
<td>128,000</td>
<td>130,000</td>
<td>130,000</td>
<td>130,000</td>
<td>130,000</td>
</tr>
<tr>
<td>City B</td>
<td>210,000</td>
<td>210,000</td>
<td>215,000</td>
<td>216,654</td>
<td>218,321</td>
<td>220,000</td>
<td>225,000</td>
<td>225,000</td>
</tr>
<tr>
<td>City C</td>
<td>60,000</td>
<td>65,000</td>
<td>68,176</td>
<td>71,506</td>
<td>75,000</td>
<td>77,000</td>
<td>77,000</td>
<td>77,000</td>
</tr>
<tr>
<td>City D</td>
<td>150,000</td>
<td>156,391</td>
<td>163,053</td>
<td>170,000</td>
<td>175,000</td>
<td>177,000</td>
<td>180,000</td>
<td>182,000</td>
</tr>
</tbody>
</table>

*using Excel growth function for filling in data within a time series and assuming no change after latest year available
Based on these data the population weighted averages were calculated for the four cities. The calculation was done in Excel, using for each year the sumproduct function for benzoylecgonine found in the four cities and the population in the four catchment areas; the resulting total was then divided by the total population in the four waste-water catchment areas in the respective year to arrive at the average (i.e. for 2018: \((97*130,000 + 90*225,000 + 180*77,000 + 130*182,000) / \text{sum}(130,000 + 225,000 + 77,000 + 182,000) = 115\)

### Calculation of average of benzoylecgonine per 1000 inhabitants in four cities

<table>
<thead>
<tr>
<th>Year</th>
<th>Average for cities A, B, C, D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>95</td>
</tr>
<tr>
<td>2012</td>
<td>93</td>
</tr>
<tr>
<td>2013</td>
<td>95</td>
</tr>
<tr>
<td>2014</td>
<td>98</td>
</tr>
<tr>
<td>2015</td>
<td>105</td>
</tr>
<tr>
<td>2016</td>
<td>110</td>
</tr>
<tr>
<td>2017</td>
<td>113</td>
</tr>
<tr>
<td>2018</td>
<td>115</td>
</tr>
</tbody>
</table>

**Estimates of the prevalence of injecting drug use, HIV and hepatitis (C and B virus) among people who inject drugs (PWID)**

Data sources, selection of country estimates and validation process

Population size estimates for PWID, and the prevalence of HIV and hepatitis among PWID, were identified over the past six years using a comprehensive search of the published peer-reviewed literature, a search of the “grey” literature, from the official United Nations survey instruments of UNODC and UNAIDS, from regional organizations (particularly the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)), and through the global network of UNODC HIV/AIDS Advisors.

The criteria for the selection of country estimates primarily involved the consideration of the methodological soundness of the estimates, determined according to the classification presented in the table below (studies in class A are of higher methodological quality and those in class D of lower quality), with due regard to national geographic coverage, the year of the estimate, and the definition of the target population (global and regional estimates were made for the annual prevalence of injecting among both genders aged 15-64). UNODC, WHO, UNAIDS and the World Bank reviewed all estimates.
Table: Classification of methodology for people who inject drugs, and those among them living with HIV and hepatitis

Data are categorized by methodology according to a slightly modified classification originally proposed in Mathers et. al. (2008) Lancet paper.6

<table>
<thead>
<tr>
<th>Class</th>
<th>Data on people who inject drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Indirect prevalence estimation methods</td>
</tr>
<tr>
<td></td>
<td>e.g., capture-recapture, network scale-up method, multiplier methods, etc</td>
</tr>
<tr>
<td>B1</td>
<td>Mapping/census and enumeration</td>
</tr>
<tr>
<td>B2</td>
<td>General population survey</td>
</tr>
<tr>
<td>C</td>
<td>Treatment and other national registers of drug users</td>
</tr>
<tr>
<td></td>
<td>- Official government estimate with no methodology reported</td>
</tr>
<tr>
<td></td>
<td>- Experts’ judgment with known method of estimation (eg. an estimate obtained through a rapid assessment)</td>
</tr>
<tr>
<td></td>
<td>- Modelling studies (e.g. Spectrum)</td>
</tr>
<tr>
<td></td>
<td>- Delphi method or other consensus estimate</td>
</tr>
<tr>
<td>D1</td>
<td>Estimate from non-official source with methodology unknown</td>
</tr>
<tr>
<td>D2*</td>
<td>Estimate from non-official source with methodology unknown</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Class</th>
<th>Data on the prevalence of HIV and hepatitis among people who inject drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Seroprevalence study</td>
</tr>
<tr>
<td>A1</td>
<td>Multi-site seroprevalence study with at least two sample types (e.g. treatment or outreach sample)</td>
</tr>
<tr>
<td>A2</td>
<td>Seroprevalence study from a single sample type</td>
</tr>
<tr>
<td>B</td>
<td>Registration or notification of cases of HIV infection (e.g. from treatment services)</td>
</tr>
<tr>
<td>C</td>
<td>Prevalence study using self-reported HIV</td>
</tr>
<tr>
<td>D1</td>
<td>- Official government estimate with no methodology reported</td>
</tr>
<tr>
<td></td>
<td>- Modelling Studies (e.g. mode of transmission models)</td>
</tr>
<tr>
<td>D2*</td>
<td>Estimate from non-official source with methodology unknown</td>
</tr>
</tbody>
</table>

*Data graded D2 are excluded from the dataset

As part of a wider review process, every year since 2014, UNODC, WHO, UNAIDS and the World Bank have reached out to a broad group of experts from academia (including all former members of the Reference Group to the United Nations on HIV and Injecting Drug Use) and regional, international, including civil society, organizations to ensure that a scientific approach to the methodology was used and that the greatest number of datasets available worldwide on the subject were included. Data were sent to Member States annually for their validation and potential comments on the selected estimates, or for completion of data if surveys had been conducted which UNODC was not aware of.

Calculation of regional and global estimates

Regional and global estimates were calculated for a specific reference year. Presently this is for 2017 (as for most of the data presented in the World Drug Report 2019).

The regional best estimates for the prevalence of injecting drug use, and HIV and hepatitis among PWID, were calculated as the population-weighted means. The global estimates for 2017 were calculated as the population-weighted regional means. In the population-weighting procedure, the population refers to those aged 15-64 years for the year 2017 in the case of the prevalence of injecting drug use, or to the estimated number of PWID for the year 2017 in the case of the prevalence of HIV and hepatitis among PWID. For countries where a number of PWID was reported in the study/survey, a prevalence estimate was subsequently calculated using the population aged 15-64 corresponding to the year of the estimate. For those countries where an estimate of the prevalence of HIV or hepatitis among PWID was available, but a population size estimate for PWID was not, then the regional average prevalence of injecting drug use was used to produce a population size estimate for PWID that was used in the weighting procedure for the prevalence of HIV and hepatitis among PWID.

Uncertainty intervals for the regional and global best estimates were calculated that reflect both the range in the country prevalence estimates (if these were provided) and the regional variability in the available country prevalence estimates. To achieve this, the 10th and 90th percentiles of the known prevalence estimates for countries from within the same region were determined. These were then applied to countries from within the same region for which no estimates were available to give a range of plausible population size estimates. This produced a liberal uncertainty range while excluding the extreme prevalence estimates.

Data quality of estimates on injecting drug use and HIV among PWID

Interpretation of regional and global estimates

The global and regional estimates for the prevalence of injecting drug use and HIV among PWID presented for 2017 in the World Drug Report should be viewed as an update to those presented in previous editions of the World Drug Report that reflect the latest data available. This year new or updated information was identified on PWID from 31 countries and on HIV among PWID from 37 countries. There is no intention to imply that there has been an actual change in the prevalence of injecting drug use or HIV among PWID at the regional or global
level. The new values represent an update based on the best estimates that can currently be made using the most recent and highest quality data available to UNODC, WHO, UNAIDS, and the World Bank.

Quality of national-level data on PWID

Of the 110 countries with information on the prevalence of PWID, 64 per cent were of high methodological quality (class A, as defined in the table above) and 69 per cent related to timely data from 2013 or more recently. Almost one-half (42 per cent) of the countries have information that is from recent, methodologically high quality surveys. With a low level of coverage of the population aged 15-64 compared to other regions there is limited information on PWID for countries in Africa. It is noticeable that there are relatively few recent, methodologically high quality data from the Americas. However, for the two sub-regions with the highest prevalence of PWID (Eastern and South-Eastern Europe, and Central Asia and Transcaucasia) there is a very high percentage data coverage of the populations aged 15-64 and approximately one half or more of the estimates are both recent and of high methodological quality.

Quality of national-level data on HIV among PWID

Of the 121 countries with information on the prevalence of HIV among PWID, 70 per cent were of high methodological quality (class A, as defined in the table above) and 51 per cent related to timely data from 2015 or more recently. Almost one third (31 per cent) of the countries have information that is from both recent and methodologically high quality surveys. The two sub-regions that have by far the highest prevalence of HIV among PWID (South-West Asia, and Eastern and South-Eastern Europe) have prevalence estimates from all countries and from methodologically high quality surveys from a good percentage of those countries.
Table: Population coverage, timeliness and methodological quality of information from the 110 countries with data on people who inject drugs

<table>
<thead>
<tr>
<th>Region</th>
<th>Subregion</th>
<th>Percentage coverage in terms of population aged 15-64</th>
<th>Percentage coverage in terms of countries</th>
<th>Of countries with available estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Percentage with recent data (2013 or more recent)</td>
<td>Percentage with high methodological quality (class A)</td>
<td>Percentage both recent and of high methodological quality</td>
</tr>
<tr>
<td>Africa</td>
<td></td>
<td>58</td>
<td>76</td>
<td>43</td>
</tr>
<tr>
<td>America</td>
<td></td>
<td>86</td>
<td>71</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Northern America</td>
<td>100</td>
<td>67</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Latin America and the Caribbean</td>
<td>73</td>
<td>73</td>
<td>18</td>
</tr>
<tr>
<td>Asia</td>
<td>Central Asia and Transcaucasia</td>
<td>94</td>
<td>71</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>East and South-East Asia</td>
<td>95</td>
<td>69</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>South-West Asia</td>
<td>100</td>
<td>33</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Near and Middle East</td>
<td>39</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>South Asia</td>
<td>100</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Europe</td>
<td>Eastern and South-Eastern Europe</td>
<td>90</td>
<td>63</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>Western and Central Europe</td>
<td>83</td>
<td>54</td>
<td>85</td>
</tr>
<tr>
<td>Oceania</td>
<td></td>
<td>73</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td>88</td>
<td>69</td>
<td>64</td>
</tr>
</tbody>
</table>

Sources for original estimates on PWID: UNODC annual report questionnaire, progress reports of UNAIDS on the global AIDS response (various years), the former Reference Group to the United Nations on HIV and Injecting Drug Use, peer-reviewed journal articles, study/survey reports and national government reports.

Table: Population coverage, timeliness and methodological quality of information from the 119 countries with data on the prevalence of HIV among people who inject drugs

<table>
<thead>
<tr>
<th>Region</th>
<th>Subregion</th>
<th>Percentage coverage in terms of estimated number of people who inject drugs</th>
<th>Percentage coverage in terms of countries</th>
<th>Of countries with available estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Percentage with recent data (2015 or more recent)</td>
<td>Percentage with high methodological quality (class A)</td>
<td>Percentage both recent and of high methodological quality</td>
</tr>
<tr>
<td>Africa</td>
<td></td>
<td>75</td>
<td>42</td>
<td>88</td>
</tr>
<tr>
<td>America</td>
<td></td>
<td>94</td>
<td>30</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Northern America</td>
<td>100</td>
<td>67</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Latin America and the Caribbean</td>
<td>75</td>
<td>8</td>
<td>50</td>
</tr>
<tr>
<td>Asia</td>
<td>Central Asia and Transcaucasia</td>
<td>94</td>
<td>57</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>East and South-East Asia</td>
<td>99</td>
<td>60</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>South-West Asia</td>
<td>100</td>
<td>33</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Near and Middle East</td>
<td>56</td>
<td>56</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>South Asia</td>
<td>100</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>Europe</td>
<td>Eastern and South-Eastern Europe</td>
<td>100</td>
<td>61</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Western and Central Europe</td>
<td>100</td>
<td>54</td>
<td>69</td>
</tr>
<tr>
<td>Oceania</td>
<td></td>
<td>73</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td>96</td>
<td>51</td>
<td>70</td>
</tr>
</tbody>
</table>

Sources for original estimates on HIV among PWID: UNODC annual report questionnaire, progress reports of UNAIDS on the global AIDS response (various years), the former Reference Group to the United Nations on HIV and Injecting Drug Use, peer-reviewed journal articles, study/survey reports and national government reports.
Estimates on the number of drug-related deaths (mortality)

Deaths caused by drug use can be directly related to drug use disorders, such as overdoses, or can be indirectly related to drug use, such as from HIV/AIDS or hepatitis C acquired through unsafe injecting practices.

It is important to note that Member States report on drug-related deaths according to their own definitions and therefore caution should be taken when making country comparisons. The total number of drug-related deaths reported by Member States was used to determine a mortality rate per 1 million population aged 15-64 years, using population figures from the World Population Prospects (WPP 2017 Revision), published by the United Nations Population Division (Department of Economic and Social Affairs).

3. Drug cultivation, production and manufacture

Data on cultivation of opium poppy and coca bush and production of opium and coca leaf for the main producing countries (Afghanistan, Myanmar and the Lao People’s Democratic Republic, for opium; and Colombia, Peru and the Plurinational State of Bolivia for coca) are mainly derived from national monitoring systems supported by UNODC in the framework of the Global Illicit Crop Monitoring Programme (ICMP). The detailed country reports can be found on the UNODC website https://www.unodc.org/unodc/en/crop-monitoring/index.html

UNODC estimates for Afghanistan cover the period 1994-2018. UNODC supported monitoring systems in most other countries started following UNGASS 1998, became operational over the 2000-2002 period and have reported data ever since. Opium cultivation and production estimates are available up to the year 2018.

The preliminary opium poppy cultivation data for 2017 have been revised as new information from missing countries became available and some country results were revised. The total area under opium poppy cultivation estimated for the year 2017 thus decreased slightly, from 418,000 hectares reported in the 2018 World Drug Report, to 414,500 hectares reported in the 2019 World Drug Report. Similarly, estimates for 2016 were adjusted as well, from 305,300 hectares under opium poppy cultivation globally as reported in the 2018 World Drug Report, to 294,500 hectares in the current 2019 World Drug Report.

Preliminary data for 2018 – 345,800 hectares - should be also interpreted with caution. No opium poppy surveys took place in 2018 in the Lao PDR. Estimates of the area under opium
Poppy cultivation in Mexico are for the season 2016/2017. No data for the season 2017/2018 are as yet available. Data published for Mexico up until the year 2014 have been based on estimates provided by the US State Department in its annual International Narcotics Control Strategy Report (INCSR) and are – for methodological reasons – not directly comparable with the new estimates from the new Mexican crop monitoring system (supported by UNODC).

Opium poppy cultivation in countries which do not conduct area surveys, was estimated with an indirect method (see below). The global opium poppy cultivation estimates for 2018 will be adjusted again in next year’s World Drug Report once more data will have become available.

Preliminary estimates suggest that global opium production in 2018 amounted to some 7,790 tons, a decrease from the of 10,415 tons estimated for 2017, the highest value on record since UNODC started its annual monitoring of opium production at the beginning of the 21st century. Earlier estimates exist, but a comparison of opium poppy cultivation and opium production estimates with estimates from previous decades, notably those reported for periods prior to World War II are rendered difficult as the methodologies then used differ from the methodologies used nowadays. Opium production estimates are nowadays derived from an analysis of satellite photos for the analysis of the area under cultivation. This area is then multiplied with the respective yields of opium per hectare found in specific regions, as derived from detailed yield surveys. In contrast, opium production estimates at the turn of the 19th to the 20th century were mainly derived from a detailed analysis of tax payments and other levies of opium poppy farmers to the authorities.

Such global opium production estimates reported in the proceedings of the Shanghai Opium Commission, 1909, revealed e.g. a global opium production of 41,600 tons of opium for the period 1906/07. For the year 1934 official reports by the League of Nations saw a global opium production of some 16,600 tons.

Comparisons are further complicated by the fact that the legal status of opium production was not always clear in the 19th century and the early decades of the 20th century, i.e. data

---

8 UNODC, A Century of International Drug Control, 2009.
reported usually comprised both legal and illegal production of opium. Thus, long-term comparisons should be made with estimates for legal and illegal opium production combined.

In addition to illegal production of some 7,790 tons in 2018, legal production of opium in 2018 amounted to – based on preliminary estimates by the International Narcotics Control Board - some 229 tons in 2018 (produced on some 5,400 ha).

However, this calculation does not take into account that much of the licit source of morphine production nowadays is in the form of poppy straw rather than in the form of opium as such.

The next question is how best to convert such poppy straw data into opium equivalents. One possibility is to calculate the morphine produced out of the poppy straw and to find out how much opium would have been needed to produce such amounts of morphine. The International Narcotics Control Board reported for 2017 a global cultivation of poppy straw on 71,700 ha, resulting in a licit production of 29,478 tons of poppy straw for the extraction of morphine.

Due to higher production in previous years, a total of 40,905 tons of poppy straw was used for the further processing into morphine in 2017, including 38,447 tons for the manufacture of an anhydrous morphine alkaloid concentrate of poppy straw containing morphine as the main alkaloid (AMA) and 2,457 tons for the direct conversion of poppy straw into morphine. Globally, 360 tons of morphine out of AMA and 17 tons of morphine directly out of poppy straw were manufactured in 2017, i.e. in total 377 tons of morphine out of 40,905 tons of poppy straw. Given an overall lower poppy straw production of 29,478 tons in 2017 (i.e. 72 per cent of the poppy straw used in the manufacture of morphine in that year), one can assume that this would have been sufficient to have produced 271 tons of morphine (377 * 0.72) in 2017. However, there are indications that the area under poppy straw cultivation increased again in 2018. Thus, the actual amounts of morphine manufactured out of poppy straw in 2017 (377 tons) may be a better proxy for poppy straw production in 2018 than actual poppy straw production reported for the year 2017.

The INCB report also shows that out of 492 tons of opium used in this year for the manufacture of morphine, 45 tons of morphine were obtained in that year, equivalent to a yield of 0.0918. Applying such a yield to the 377 tons of morphine potentially obtained from poppy straw production suggests that some 4,107 tons of opium may have been needed to produce such a quantity of morphine. Applying such a figure as a proxy for legal opium

34
production in 2018, would suggest that legal opium production may have amounted to some 4,336 tons (i.e. 229 tons opium opium + 4,107 tons of poppy straw converted into poppy equivalents), which would have to be added to the illicit opium production of 7,790 tons to arrive at an overall opium production of – rounded - some 12,100 tons in 2018.

Such licit and illicit opium production would be still significantly less than the licit and illicit opium production reported for the year 1906/07 (41,600 tons of opium) or the year 1934 (16,600 tons) even though direct comparability remains limited due to changes in the methodologies used.

Coca cultivation estimates in the three main Andean coca producing countries were available – at the time of drafting the World Drug Report - up to the year 2017. Results for the year 2018 will be published on UNODC’s website as soon as the new reports will have been released in 2019.

Estimates of cannabis cultivation in 2009, 2010, 2011 and 2012 in Afghanistan, as well as cannabis cultivation in 2003, 2004 and 2005 in Morocco, were also produced by the UNODC-supported national monitoring systems and can be found on the UNODC website. Estimates for other countries were drawn from ARQ replies and various other sources, including reports from Governments, UNODC field offices and the United States Department of State's Bureau for International Narcotics and Law Enforcement Affairs.

A full technical description of the methods used by UNODC-supported national monitoring systems can be found in the respective national survey reports available at https://www.unodc.org/unodc/en/crop-monitoring/index.html

**Net cultivation**

Not all the fields on which illicit crops are planted are actually harvested and contribute to drug production. For Afghanistan, a system of monitoring opium poppy eradication is in place which provides all necessary information to calculate the net cultivation area. In Myanmar and the Lao People’s Democratic Republic, only the area of opium poppy eradicated before the annual opium survey is taken into account for the estimation of the cultivation area. Not enough information is available to consider eradication carried out after the time of the annual opium survey.
A major difference between coca and other narcotic plants such as opium poppy and cannabis is that the coca bush is a perennial plant which can be harvested several times per year. This longevity of the coca plant should, in principle, make it easier to measure the area under coca cultivation. In reality, the area under coca cultivation is dynamic, making it difficult to determine the exact amount of land under coca cultivation at any specific point in time or within a given year. There are several reasons why coca cultivation is so dynamic, including new plantation, abandonment, reactivation of previously abandoned fields, manual eradication and aerial spraying.⁹

The issue of different area concepts and data sources used to monitor illicit coca bush cultivation was repeatedly investigated by UNODC.¹⁰ To improve the comparability of estimates between countries and years, since 2011 net coca cultivation area at 31 of December is presented not only for Colombia but also for Peru. For technical reasons, the initial area measurement of coca fields takes place on satellite images acquired at different dates of the year and sometimes having different technical specifications. For the Plurinational State of Bolivia, in contrast, most satellite images are taken close to the 31 of December in order to reduce potential errors linked to subsequent eradication. In any case, for the Bolivian and Peruvian estimate, these differences are considered to have a limited effect only, whereas the dynamic situation in Colombia requires more adjustments to maintain year-on-year comparability. For more details, please see the country specific reports.

**Indirect estimation of illicit opium poppy cultivation**

Eradication and plant seizure reports indicate that illicit opium poppy cultivation exists in many countries, which do not regularly conduct illicit crop surveys. Starting 2008 a new methodology was introduced to estimate the extent of this illicit cultivation with an indirect method based on two indicators available in UNODC’s databases: eradicated poppy area and opium poppy (plant, capsule) seizures reported as units or weight.

*Prioritization of data sources:* Whenever possible, the eradicated poppy area was used as this indicator is conceptually closest. If this indicator was not available, poppy plant seizure data was used, which requires an additional conversion of the seized amount into area eradicated.

---

⁹ Plant disease and pests are not considered here as their impact is likely to be captured in the coca leaf yield estimates.

It can be assumed that plant seizures are often a different way of recording eradication. e.g. in cases where area measurements are technically difficult or because the law requires all seized material to be weighed even if the seizure consists actually of eradicated plants on a field. Large-scale or long-distance illicit trade with opium poppy plants is unlikely as the plants are bulky, perishable and of low value.

**Eradication factor:** Evidence from countries which provide both illicit cultivation and eradication data indicates that illicit cultivation is typically a multiple of the area eradicated. This relationship, averaged over the last five years for which information is available, was used to calculate a factor which allowed to estimate illicit cultivation in countries from eradication figures. Since 2008, this factor is based on opium poppy cultivation and eradication data from Colombia, Lao People’s Republic, Mexico, Myanmar, Pakistan and Thailand. Over the years, the average over these five countries ranged between 2.1 and 3.0 (eradicated area * factor = net cultivation area). (Afghanistan was not considered for the calculation of the factor as the objective was to estimate low to mid-levels of illicit cultivation. Afghanistan, representing two thirds or more of global illicit poppy cultivation, clearly fell outside this range).

**Plant seizures:** seizures of poppy plant material usually happen close to the source, i.e. in vicinity of the cultivated area. The data available to UNODC does not allow to accurately and systematically differentiate between the various parts (capsules, bulbs, entire plants) of the plant seized as for plant seizures. Most (roots, stem, leaves, capsules) or only some parts (poppy straw, capsules only) of the plant may be seized. While this does not influence seizure data given in plant units, it plays a role when interpreting seizure data given as weight.

**Plant seizure data in units** represent plant numbers, which can be converted into area (ha) using an average number of opium poppy plants per hectare. Yield measurements from Afghanistan and Myanmar, where UNODC has conducted yield surveys over several years, indicate an average figure of about 190,000 plants per hectare. Dividing poppy plant seizure numbers by this factor results in estimate of the area on which the seized material was cultivated. This is equivalent to eradicated area, as the seized material was taken out of the production cycle. Eradicated area multiplied with the eradication factor described above yields then cultivation area.
Plant seizure data reported as weight: In order to convert the weight of seized poppy plants into area, a typical biomass per hectare of poppy was estimated based on the evaluation of various sources. The biomass yield in oven-dry equivalent including stem, leaves, capsule and seeds reported by a commercial licit opium poppy grower in Spain\textsuperscript{11} was 2,800 kg/ha for rain-fed and 7,800 kg/ha for irrigated fields respectively. Information on the weight of roots was not available. Loewe\textsuperscript{12} found biomass yields between 3,921 kg/ha to 5,438 kg/ha in trial cultivation under greenhouse conditions. Acock et al.\textsuperscript{13} found oven-dry plant weights of about 37 grams including roots in trials under controlled conditions corresponding to a biomass yield of around 7,000 kg/ha with the assumed plant density of 190,000/ha. Among the available biomass measurements only the figures from Spain referred to poppy grown under field conditions. All other results fell into the range between the non-irrigated and irrigated biomass yields (2,800 – 7,800 kg/ha) reported. For purposes of this calculation the simple average of these two values was taken.

Two caveats have to be made: a) As the reporting format does not differentiate between capsules and plants or between the different growth stages of a poppy plant, it was assumed that the reported weight refers to whole, mature plants. This leads to a conservative estimate as many plant seizures are actually carried out on fields before the poppy plants reach maturity. b) The reference biomass measurements from scientific studies are expressed in oven-dried equivalents, whereas the reported weights could refer to fresh weight or air-dry weight; both of which are higher than the oven-dry equivalent weight equivalent. This would lead to an over-estimation of the illicit cultivation area. In the case of young plants, which are typically fresh but not yet fully grown, both errors could balance off, whereas in the case of mature or harvested plants, which tend to be drier, both errors would be smaller.

In order to avoid the fluctuations typically present in seizure and eradication data, the above calculations were based on plant seizures averaged over the most recent five-year period, rather than datapoints relative to the specific year. If no eradication or plant seizure was reported in that period, no value was calculated.

\textsuperscript{11} Personal communication, 2010, from Alcaliber company.
Yield\textsuperscript{14} and production

To estimate potential production of opium, coca leaf and cannabis (herb and resin), the number of harvests per year and the total yield of primary plant material has to be established. The UNODC-supported national surveys take measurements in the field and conduct interviews with farmers, using results from both to produce the final data on yield.

Opium yield surveys are complex. Harvesting opium with the traditional lancing method can take up to two weeks as the opium latex that oozes out of the poppy capsule has to dry before harvesters can scrape it off and several lancings take place until the plant has dried. To avoid this lengthy process, yield surveyors measure the number of poppy capsules and their size in sample plots. Using a scientifically developed formula, the measured poppy capsule volume indicates how much opium gum each plant potentially yields. Thus, the per hectare opium yield can be estimated. Different formulas were developed for South-East and South-West Asia. In Afghanistan, yield surveys are carried out annually; in Myanmar regularly.

For coca bush, the number of harvests varies, as does the yield per harvest. In the Plurinational State of Bolivia and Peru, UNODC supports monitoring systems that conduct coca leaf yield surveys in several regions, by harvesting sample plots of coca fields over the course of a year, at points in time indicated by the coca farmer. In these two countries, yield surveys are carried out only occasionally, due to the difficult security situation in many coca regions and because of funding constraints. In Colombia, coca leaf yield estimates are updated yearly through a rotational monitoring system introduced in 2005 that ensures that every yield region is revisited about every three years. However, as the security situation does not allow for surveyors to return to the sample fields, only one harvest is measured, and the others are estimated based on information from the farmer. In 2013 for the first time the concept of productive area was applied to calculate the coca leaf yields in Colombia, taking into account the dynamics of the fields due to spraying and eradication for which some fields are only partly productive during the year. This new way of calculating was retroactively applied to the results of 2005-2012, giving slightly different results than published before\textsuperscript{15}.

\textsuperscript{14} Further information on the methodology of opium and coca leaf yield surveys conducted by UNODC can be found in United Nations (2001): \textit{Guidelines for Yield Assessment of Opium Gum and Coca Leaf from Brief Field Visits}, New York (ST/NAR/33).

\textsuperscript{15} More information on the results of the methodology used can be found in the report on coca cultivation in Colombia for 2013 (UNODC/ Government of Colombia, June 2014) available on the internet at http://www.unodc.org/unodc/en/crop-monitoring/index.html.
In Peru and Bolivia the additional production of partly productive areas is not considered for
the coca leaf yield estimates.\textsuperscript{16}

\textit{Conversion factors}

The primary plant material harvested - opium in the form of gum or latex from opium poppy,
coca leaves from coca bush, and the cannabis plant - undergo a sequence of extraction and
transformation processes, some of which are done by farmers onsite, others by traffickers in
clandestine laboratories. Some of these processes involve precursor chemicals and may be
done by different people in different places under a variety of conditions, which are not
always known. In the case of opium gum, for example, traffickers extract the morphine
contained in the gum in one process, transform the morphine into heroin base in a second
process, and finally produce heroin hydrochloride. In the case of cocaine, coca paste is
produced from either sun-dried (in the Plurinational State of Bolivia and Peru) or fresh coca
leaves (in Colombia), which is later transformed into cocaine base, from where cocaine
hydrochloride is produced.

The results of each step, for example from coca leaf to coca paste, can be estimated with a
conversion factor. Such conversion factors are based on interviews with the people involved
in the process, such as farmers in Colombia, who report how much coca leaf they need to
produce 1 kg of coca paste or cocaine base. Tests have also been conducted where so-called
‘cooks’ or ‘chemists’ demonstrate how they do the processing under local conditions. A
number of studies conducted by enforcement agencies in the main drug-producing countries
have provided the orders of magnitude for the transformation from the raw material to the
end product. This information is usually based on just a few case studies, however, which are
not necessarily representative of the entire production process. Farmer interviews are not
always possible due to the sensitivity of the topic, especially if the processing is done by
specialists and not by the farmers themselves. Establishing conversion ratios is complicated
by the fact that traffickers may not know the quality of the raw material and chemicals they
use, which may vary considerably; they may have to use a range of chemicals for the same
purpose depending, on their availability and costs; and the conditions under which the
processing takes place (temperature, humidity, et cetera) differ.

\textsuperscript{16} In 2013 a correction factor was applied for the time that fields in Peru were productive during the year,
however this approach was abolished as of 2014 due to incomplete eradication data. More information about the
2013 calculation to be found at page 73 of the Peru coca cultivation survey report for 2013 available on the
It is important to take into account the fact that the margins of error of these conversion ratios – used to calculate the potential cocaine production from coca leaf or the heroin production from opium - are not known. To be precise, these calculations would require detailed information on the morphine content of opium or the cocaine content of the coca leaf, as well as detailed information on the efficiency of clandestine laboratories. Such information is limited. This also applies to the question of the psychoactive content of the narcotic plants.

UNODC, in cooperation with Member States, continues to review coca leaf to cocaine conversion ratios as well as coca leaf yields and net productive area estimates.\textsuperscript{17} More research is needed to establish comparable data for all components of the cocaine production estimate.

Many cannabis farmers in Afghanistan and Morocco conduct the first processing steps themselves, either by removing the upper leaves and flowers of the plant to produce cannabis herb or by threshing and sieving the plant material to extract the cannabis resin. The herb and resin yield per hectare can be obtained by multiplying the plant material yield with an extraction factor. The complex area of cannabis resin yield in Afghanistan was investigated in 2009, 2010, 2011 and 2012. The yield study included observation of the actual production of resin, which is a process of threshing and sieving the dried cannabis plants. In Morocco, this factor was established by using information from farmers on the methods used and on results from scientific laboratories. Information on the yield was obtained from interviews with cannabis farmers.\textsuperscript{18} Given the high level of uncertainty and the continuing lack of information for the large majority of cannabis-cultivating countries, the estimates of global cannabis herb and resin production have not been calculated.

\textit{Potential production}

‘Potential’ heroin or cocaine production refers to total production of heroin or cocaine if all the cultivated opium or coca leaf, less the opium and coca leaf consumed as such, were transformed into the end products in the respective producer country in the same year. It should be noted though that a product such as opium can be stored for extended periods of

\textsuperscript{17} More detailed information on the ongoing review of conversion factors was presented in the 2010 \textit{World Drug Report}, p.251 ff.

\textsuperscript{18} For greater detail on studies with cannabis farmers, see: UNODC, \textit{Enquête sur le cannabis au Maroc 2005}, Vienna, 2007.
time and be converted into intermediate or final products long after the harvest year. Thus ‘actual’ heroin manufacture, making use of accumulated stocks of opium from previous years, can deviate significantly from ‘potential’ heroin manufacture out of the opium produced in a specific year. Direct consumption of opium or the coca leaf, in contrast, is being taken into account. For example, consumption of coca leaf considered licit in the Plurinational State of Bolivia and Peru is deducted from the amounts of coca available for the transformation into cocaine. Other factors, such as the actual amount of illicit coca paste or opium consumption and storage, are difficult to estimate and were not taken into account. Similarly, opium consumed in Afghanistan and neighbouring countries is deducted from the amounts of opium available for heroin production. In contrast, opium stocked or opium used from stocks accumulated over previous years is not considered in the calculation of ‘potential’ heroin manufacture.

For cocaine, potential production of 100 per cent pure cocaine is estimated. In reality, clandestine laboratories do not produce 100 per cent pure cocaine but cocaine of lower purity which is often referred to as ‘export quality’.

For heroin, two conversion ratios are used. Apart from Afghanistan, not enough information is available to estimate the production of heroin at 100 per cent purity. Instead, potential production of export quality heroin is estimated, whose exact purity is not known and may vary. For Afghanistan, the calculations are more detailed. Here the share of all opium converted to heroin is estimated and a specific conversion ratio is applied, which uses an estimated purity for heroin of export quality, derived from wholesale purities found in other countries in the neighbourhood.

Although it is based on current knowledge on the alkaloid content of narcotic plants and the efficiency of clandestine laboratories, it should be noted that ‘potential production’ is a hypothetical concept and is not an estimate of actual heroin or cocaine production at the country or global level. The concept of potential production is also different from the theoretical maximum amount of drug that could be produced if all alkaloids were extracted from opium and coca leaf. The difference between the theoretical maximum and the potential production is expressed by the so-called laboratory efficiency, which describes which proportion of alkaloids present in plant material clandestine laboratories are actually able to extract.
Colombia

From 2013 onwards, the yearly productive areas were estimated, instead of using the average area under coca cultivation of the reporting year and the previous year (the approach used in previous reports). In addition, a different conversion factor for estimating cocaine base was applied. Both the adjustment of the productive area estimate and the estimation of the conversion factor for cocaine base were retroactively applied to the results of 2006-2012.19

Peru

Potential cocaine production in Peru is estimated from potential coca leaf production and after deducting the amount of coca leaf estimated to be used for traditional purposes according to Government sources (9,000 mt of sun-dry coca leaf).

The Plurinational State of Bolivia

Potential cocaine production in the Plurinational State of Bolivia is estimated from potential coca leaf production after deducting the amount of coca leaf produced on 12,000 ha in the Yungas of La Paz where coca cultivation is authorized under national law.

“Old” versus “new” conversion ratios for cocaine

In order to estimate cocaine production from the area under coca cultivation, the coca leaf yield per region is estimated based on yield studies as well as – based on experiments in the field - the coca-leaf to coca-paste conversion, the coca-paste to cocaine base conversion and the cocaine-base to cocaine hydrochloride conversion. The results are then adjusted to show an overall conversion ratio from coca leaf to (a potential) 100 per cent pure cocaine hydrochloride.

In this report the ‘old’ conversion ratios from coca leaf to cocaine hydrochloride are based on studies conducted by the United States Drug Enforcement Administration (DEA) in the

Andean region in the 1990s. The ratios for Colombia – in close cooperation with the Colombian authorities - were updated in 2004 and are part of the ‘old’ conversion ratio series. In subsequent years the DEA undertook new studies in Peru (2005) and in the Plurinational State of Bolivia (2007-2008), following indications that the laboratory efficiency in these countries may have improved. The ‘new’ conversion rates used in this report – for the years 2007-2017 – however, have not been reconfirmed so far in national studies as funds for such studies have not been forthcoming. For this reason, cocaine production data are not shown separately for Peru and the Plurinational State of Bolivia; only the global total based on the ‘new’ conversion ratio is shown. The calculations of cocaine production based on the “new” conversion ratios refer to the “new” coca leaf to cocaine hydrochloride transformation ratios found by the DEA for Colombia, Peru and the Plurinational State of Bolivia and the updated ratios for Colombia. It should be noted that the ‘new’ conversion ratios are still temporary; they will be updated as soon as new data, jointly established between the respective Member States and UNODC will become available (for more details, see World Drug Report 2010 (United Nations publication, Sales No. E.10.XI.13, pp. 251 and 252).

Global cocaine manufacture in tons, 1998-2017

Source: UNODC, Coca cultivation surveys in the Andean countries, 2017 and previous years.
4. Drug trafficking

Seizures

The analysis presented in this report is mainly derived from the ARQ responses from Member States up to the 2017 reporting year. Including information from other sources, UNODC was able to obtain seizure data from 123 countries and territories for 2017. Over the 2013-2017 period seizures from in total 156 countries and territories were obtained. Seizures are thus the most comprehensive indicator of the drug situation and its evolution at the global level. Although seizures may not always reflect trafficking trends correctly at the national level, they tend to show reasonable representations of trends at the regional and global levels.

Seizures are reported in volume terms as well as in terms of the number of seizure cases. The analysis of seizure cases enables a direct comparison of data across drug categories. Reporting of seizure cases is, however, less comprehensive. A total of 73 countries and territories reported seizure cases to UNODC in 2017, or 100 countries and territories over the 2011-2016 period.

Countries reporting seizures of drug in volume terms may report seizures using a variety of units, primarily by weight (kg) but also in litres, tablets, doses, blotters, capsules, ampoules, etcetera. When reporting about individual countries in individual years, UNODC endeavours to be as faithful as possible to the reports received, but often it is necessary to aggregate data of different types for the purposes of comparison. For the aggregation, conversion factors are used to convert the quantities into ‘kilogram equivalents’ (or ‘ton equivalents’). UNODC continues to record and report the disaggregated raw data, which are available in the seizure listings published at: http://www.unodc.org/unodc/en/data-and-analysis/WDR.html. In these tables, seizure quantities are reproduced as reported. In the rest of the Report, seizure data are often aggregated and transformed into this unique unit of measurement. Moreover, at some points in the analysis, purity adjustments are made where relevant and where the availability of data allows.

The conversion factors affect seizure totals of amphetamine-type stimulants (ATS), as a significant share of seizures of these drug types is reported in terms of the number of tablets. Apart from seizures of ATS tablets, drug seizures are mainly reported to UNODC by weight, and sometimes by volume. This includes seizures of ATS which are not seized in tablet form (for example, ATS in powder, crystalline or liquid form) as well as seizures of other drug
types, such as heroin and cocaine. Moreover, ATS seizures made in tablet form are also sometimes reported by weight, and in some cases, the reported total aggregated weight possibly includes ATS seized in different forms. Reports of seizures by weight usually refer to the bulk weight of seizures, including adulterants and diluents, rather than the amount of controlled substance only. Moreover, given the availability of data, accurate purity adjustments for bulk seizure totals in individual countries are feasible in only a minority of cases, as they would require information on purity on a case by case basis or statistically calibrated data, such as a weighted average or a distribution. The bulk weight of tablets is easier to obtain and less variable.

To ensure the comparability of seizure totals across different years and countries, UNODC uses conversion factors for ATS tablets intended to reflect the bulk weight of the tablets rather than the amount of controlled substance. The factors used in this edition of the *World Drug Report* are based on available forensic studies and range between 90 mg and 300 mg, depending on the region and the drug type, and also apply to other units which are presumed to represent a single consumption unit (dose). The table below lists the factors used for ATS, by type and region. The conversion factors remain subject to revision as the information available to UNODC improves.

<table>
<thead>
<tr>
<th>Weight of tablets in milligrams</th>
<th>Ecstasy (MDMA or analogue)</th>
<th>Amphetamine</th>
<th>Methamphetamine</th>
<th>Prescription stimulants</th>
<th>Other stimulants</th>
<th>Non-specified amphetamines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>271</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Asia (excluding Near and Middle East/ South-West Asia)</td>
<td>300</td>
<td>250</td>
<td>90</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Europe</td>
<td>271</td>
<td>253</td>
<td>225</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Central and South America and Caribbean</td>
<td>271</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Near and Middle East/ South-West Asia</td>
<td>237</td>
<td>170</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>North America</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Oceania</td>
<td>276</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
</tbody>
</table>

For the other drug types, the weight of a ‘typical consumption unit’ was assumed to be: for cannabis herb, 500 mg; for cannabis resin, 135 mg; cocaine and morphine, 100 mg; heroin, 30 mg; LSD, 0.05 mg (50 micrograms); and opium, 300 mg. For opiate seizures (unless specified differently in the text), it was assumed that 10 kg of opium were equivalent to 1 kg of morphine or heroin. Though these transformation ratios can be disputed, they provide a
means of combining the different seizure reports into one comprehensive measure. The transformation ratios have been derived from those normally used by law enforcement agencies, in the scientific literature and by the International Narcotics Control Board, and were established in consultation with UNODC’s Laboratory and Scientific Section. As in previous editions of the World Drug Report, seizures quantified by volume (litres) are aggregated using a conversion ratio of 1 kilogram per litre, which applies to all drug types. Cannabis plants are assumed to have an average weight of 100 grams.

Overall 125.1 tons of tramadol, 20.9 tons of codeine and 2.2 tons of fentanyl were seized in 2017 as well as 0.6 tons of other pharmaceutical opioids. Such seizure figures, however, may be misleading as doses across pharmaceutical opioids vary significantly.

Directly comparable doses are, however, difficult to identify. The most comprehensive data set in this regard are the defined daily doses for statistical purposes (S-DDD), established – with the help of experts - by the INCB. For the transformation of seizures of pharmaceutical opioids into doses such S-DDD, shown in milligrams of various substances per day, were used:

<table>
<thead>
<tr>
<th>Substance</th>
<th>S-DDD in mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetyldihydrocodeine</td>
<td>40</td>
</tr>
<tr>
<td>Alphaprodine</td>
<td>120</td>
</tr>
<tr>
<td>Anileridine</td>
<td>65</td>
</tr>
<tr>
<td>Bezitramide</td>
<td>15</td>
</tr>
<tr>
<td>Codeine (analgescic)</td>
<td>240</td>
</tr>
<tr>
<td>Codeine (cough suppressant)</td>
<td>100</td>
</tr>
<tr>
<td>Dextromoramide</td>
<td>20</td>
</tr>
<tr>
<td>Dextropropoxyphene hydrochloride</td>
<td>200</td>
</tr>
<tr>
<td>Dextropropoxyphene rapsylate</td>
<td>300</td>
</tr>
<tr>
<td>Difenoxin</td>
<td>3</td>
</tr>
<tr>
<td>Dihydrocodeine (analgescic)</td>
<td>150</td>
</tr>
<tr>
<td>Dihydrocodeine (cough suppressant)</td>
<td>100</td>
</tr>
<tr>
<td>Diphenoxylate</td>
<td>15</td>
</tr>
</tbody>
</table>
For buprenorphine, a S-DDD of 8 mg - as reported by the INCB in its annual report on Psychotropic Substances\textsuperscript{20} - was used.

No such conversion ratios, however, have been established by the INCB for tramadol as this substance is not under international control. In this case, a review of doses provided in the literature ranged from 50 to 400 mg per day with a median of around 250 mg per day. (Tramadol tablets typically contain between 50 and 250 mg, i.e. the median daily dose would be equivalent to between 1 and 5 tablets, depending on the strength of the tablet). This ratio was used as the best estimate for converting reported seizures into daily doses of seized drugs.

\textsuperscript{20} INCB, Psychotropic Substances 2018 (New York 2019).
Based on reported seizures and applying the conversion ratios mentioned above around 83 per cent of the seizures of pharmaceutical opioids in 2017 would have been in the form of fentanyl, 11 per cent in the form of tramadol and 5 per cent in the form of codeine. The rest accounted overall just for 1 per cent of the total.

In case the conversion ratio for tramadol were changed to the minimum figure found in the literature of 50 mg per day, the proportions would have amounted to: fentanyl 57 per cent; tramadol 38 per cent and codeine 3 per cent. In case the conversion ratio for tramadol were changed to 400 mg per day, fentanyl would have accounted for 87 per cent of the total, tramadol for 7 per cent and codeine for 5 per cent.

Thus, irrespective of the actual conversion ratio used for tramadol, fentanyl (for the second year in a row) would have led the seizures of pharmaceutical opioids expressed in doses, followed by tramadol and codeine.

One important caveat, however, needs to be made. Most of the fentanyl seizures in terms of quantities have been reported from the United States (96 per cent of the global total in 2017). The United States also reported very high levels of dilutions of fentanyl found on the black market, resulting in average fentanyl purity levels of just 5.1 per cent in this country in 2017. Applying such purity data for fentanyl seized in the USA while assuming 100 per cent pure fentanyl seized in other countries, the average fentanyl purity worldwide would have amounted to 8.9 per cent in 2017. Applying such a purity level to global fentanyl seizures, would result in 45 per cent of global seizures of pharmaceutical opioids accounted for by tramadol, followed by fentanyl (30 per cent), codeine (19 per cent) and other pharmaceutical opioids (6 per cent) in 2017.

Conversions into doses were also used for comparing seizures of hallucinogens. The doses of such hallucinogens differ strongly across substances. In contrast to opioids, which – except for tramadol – have been mostly under international control, many of the hallucinogens are not internationally controlled. Thus, the approach of using reported S-DDDs would have excluded many of the substances seized.

Thus, typical doses – as defined by law enforcement agencies and/or as discussed in the literature - were used instead. Thus, a dose of LSD was assumed to be equivalent to 5 micrograms, i.e. 0.00005 grams, while a dose of an NBOMe was assumed equivalent to 0.0005 grams, a dose of PCP was assumed to be equivalent to 0.008 grams, a dose of
psilocybin equivalent to 0.03 grams, a dose of dimethyltryptamine (DMT) equivalent to 0.04 grams, a dose of mescaline equivalent to 0.3 grams and a dose of ketamine was assumed to be equivalent to 0.05 grams. It goes without saying that most of these assumed doses are subject to change as soon as more reliable and systematically collected scientific data become available. Calculations have been further complicated as seizures of hallucinogens have been reported in a multitude of measures, including kilograms, pounds, grams, milligrams, millilitres, gallons, bottles, micro-dots, points, tablets, pills, capsules, trips, blotting paper, patches, stamps, sheets, pieces, units, doses etc. An attempt was made to convert all of these seizure data into “doses”.

All of such conversions are prone to errors. Nonetheless, the seizure data showed clearly that while ketamine led seizures of hallucinogens in terms of quantities seized, in terms of seizures converted into doses such seizures of hallucinogens continue being dominated by LSD. Over the 1998-2017 period 95 per cent of the total amounts of hallucinogens, expressed in doses, were accounted for by LSD, 4 per cent by ketamine and 1 per cent by other hallucinogens. LSD also dominated seizures of hallucinogens, expressed in doses, over the 2011-2017 period. Adjustments of conversion ratios for individual substances would certainly improve results, but are very unlikely to change the overall picture.

** Trafficking routes and volumes **

Information of trafficking routes was mainly obtained from analyses of reports by Member States in the annual report questionnaire and in individual drug seizures reported to UNODC, as well as analyses of trafficking routes reported by Member States.

Individual drug seizures would be the ideal data source for any in-depth analysis of drug flows. Unfortunately, reporting of individual drug seizure cases is very uneven. An average of 53 Member States reported individual drug seizures every year over the 2013-2017 period, and a significant portion do not provide information on trafficking routes or do so in a very limited manner.

Information for the maps was thus – primarily – based on information contained in the annual reports questionnaire, while individual drug seizures reports and official national documents were used to fill gaps. For the first time in 2019, two types of maps were published in the World Drug Report for each of the analysed drug types (heroin and cocaine): one based solely on seizures, and another based on both seizures and available drug use information.
Main trafficking routes as described by reported seizures

First of all, seizures made in the various regions over the 2013-2017 period were used as a proxy for the importance of drug trafficking activities. Such seizures were distributed according to the countries of departure and transit mentioned by countries in the various regions for the period 2013-2017 (outside of the regions analysed), as weighted by the total reported seizures at the national level. This served as a basis for the calculation of (likely) importance of the various trafficking flows, taking into account that drugs could be seized at different stages along the trafficking route and drugs may need to travel across several sub-regions to reach the seizing country.

A similar approach was implemented using the countries of intended destination reported by the seizing Member States. Afterwards, the flows obtained from using reported departure/transit and destination information separately were put together to estimate the final relative size of the flow. This procedure was implemented at the sub-regional level to produce a matrix of flows across sub-regions. Afterwards, the main countries of departure or transit (and destination) were identified based on the weighted amounts that were seized while being trafficked from (to) them, according to reported seizures by Member States.

Main trafficking flows based on use and seizures data

Given the underground nature of drug trafficking, it is virtually impossible to obtain a full picture with reliable data on the routes used by traffickers and the volumes that these represent. Seizures data is used as a proxy, but it has many limitations, notably the fact that different regions and countries differ in their seizing capacities, which could result in biases when using solely this type of information. Therefore, using other sources of data and triangulating the available information, could help paint a more complete picture. In this context, these maps were created using available seizures and drug use data.

While ideally this methodology would make use of consumption information (e.g., average annual consumption per user or per capita), this data is extremely scarce and available only in a very limited number of countries. Hence, information reported on the prevalence of heroin and cocaine was used to establish the share of drugs consumed at the global level that each sub-region represents.
Based on these sub-regional consumption levels, for each type of drug, the matrix of flows at the sub-regional level created in the map described above was used to estimate the flows between sub-regions necessary to satisfy these consumption needs (and for further transit to other consuming sub-regions). This procedure was done in an iterative manner to account for the different steps of trafficking across sub-regions.

**Drug price and purity data**

Price and purity data, if properly collected and reported, can be powerful indicators of market trends. Trends in supply can change over a shorter period of time when compared with changes in demand and shifts in prices and purities are relatively good indicators for increases or declines of market supply. Research has shown that short-term changes in the consumer markets are first reflected in purity changes while prices tend to be rather stable over longer periods of time. UNODC collects its price data from the ARQ, and supplements this data with other sources such as DAINAP, EMCDDA and Government reports. Prices are collected at farm-gate level, wholesale level (‘kilogram prices’) and at retail level (‘gram prices’). Countries are asked to provide minimum, maximum and typical prices and purities. When countries do not provide typical prices/purities, for the purposes of certain estimates, the mid-point of these estimates is calculated as a proxy for the ‘typical’ prices/purities (unless scientific studies are available which provide better estimates). What is generally not known is how data were collected and how reliable it is. Although improvements have been made in some countries over the years, a number of law enforcement bodies have not yet established a regular system for collecting purity and price data.

Prices are collected in local currency or in the currency in which the transactions take place and are then converted by UNODC into US dollars for the purposes of comparability among countries. The conversion into US dollars is based on official UN rates of exchange for the year. If comparisons of prices, expressed in US dollars are made over different years it should be noted that changes in such prices may be also influenced by changes in the exchange rates and may not necessarily reflect changes in the local markets.

*Standardized prices of cocaine and heroin in the United States and Western Europe*

Some of the figures presented in the statistical annex Table 3 available in [http://www.unodc.org/wdr2019](http://www.unodc.org/wdr2019) can follow a different methodology than the one described above.
For the case of heroin and cocaine prices in the 17 European countries in this Table, the published prices correspond an average of the available prices for the specific year (e.g., “crack” and cocaine salts, or white and brown heroin), if more than one type of drug is reported, or the typical value if only one price is reported by the country. In order to properly calculate the weighted averages across the 17 European Member States, in those countries for which no data is available, a “best estimate” is reported. This “best estimate” is based on: a) the latest reported value, b) an interpolation between two reported values, or c) the midpoint between the reported low and high observed prices (when a typical value is not available).

In order to properly reflect the prices faced by the population within these 17 countries, the average prices are weighted by the population. A reported average price per gram in Euro is also published based on the average exchange rates for the corresponding year, and the reported units (gram for retail, kilogram for wholesale). Finally, the inflation-adjusted weighted average is expressed in 2017 Euro, by deflating the prices using the Consumer Price Index (CPI) published by Eurostat.

For the case of heroin and cocaine average prices at the retail level in the United States of America, both series were reviewed this year given the availability of new data. Authorities from the United States of America provided UNODC with newly available quarterly data on the price and purity of cocaine and heroin at the retail level for the 2005-2016 period. The average quarterly price for each of these years is reported. For the price of cocaine in 2017, data published in the National Drug Threat Assessment\(^2\) for the first quarter of the year is used, while the 2017 price of heroin at the retail level is imputed by using the 2016 figure as no other data is available. In the case of years prior to 2005, the yearly trends from the previously published series are used to retropolate the price available for 2005. These trends are based on ARQ data and data from ONDCP, *2015 National Drug Control Strategy - 2015 Data Supplement*.

In the calculation of purity adjusted average heroin prices, the purity provided by national authorities at the quarterly level are used for 2005-2016, while data available through the ARQ or published in ONDCP, *2015 National Drug Control Strategy - 2015 Data Supplement* are used for previous years. In the calculation of purity adjusted cocaine prices, data from ONDCP is also used up to the year 2004.

Inflation adjusted prices in the United States were deflated using the CPI, published by the Bureau of Labor Statistics.